A novel CD19-directed CAR-NK cell therapy is advancing through multiple autoimmune disease trials, with a focus on safety, outpatient accessibility, and durable remissions. Key data updates in 2026 will inform future development, with redosing flexibility and regulatory engagement planned.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.